Drug Trial Radar · NCT05670951
Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants
Last checked: Nov 20, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
360
Planned (sponsor's estimate)
Start
Feb 27, 2025
Primary completion
Nov 2027
Study completion May 2029
Sponsor
- Lead sponsor
- Elgan Pharma Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 4, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 day, up to 5 days
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the effect of ELGN-2112 on intestinal malabsorption in preterm infants.
Conditions
- Intestinal Malabsorption
Interventions
ELGN-2112Drug
Human insulin \[rDNA\]
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Numbers of days to achieve full enteral feedingTime frame: 28 days or discharge from hospital
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Laniado Hospital
Netanya, Israel · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.